Food and Drug Administration, HHS.
The Food and Drug Administration (FDA or Agency) is withdrawing approval of 10 abbreviated new drug applications (ANDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.
Approval is withdrawn as of December 10, 2018.
Start Further Info
FOR FURTHER INFORMATION CONTACT:
Trang Tran, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 75, Rm. 1671, Silver Spring, MD 20993-0002, 240-402-7945, Trang.Tran@fda.hhs.gov.
End Further Info
Start Supplemental Information
The applicants listed in the table have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications under the process described in § 314.150(c) (21 CFR 314.150(c)). The applicants have also, by their requests, waived their opportunity for a hearing. Withdrawal of approval of an application or abbreviated application under § 314.150(c) is without prejudice to refiling.Start Printed Page 56087
|ANDA 040747||Benzphetamine Hydrochloride (HCl) Tablets, 25 milligrams (mg) and 50 mg||Tedor Pharma, Inc., 400 Highland Corporate Dr., Cumberland, RI 02864.|
|ANDA 062356||Gentamicin Sulfate Injection USP, Equivalent to (EQ) 10 mg base/milliliter (mL) and EQ 40 mg base/mL||Fresenius Kabi USA, LLC, Three Corporate Dr., Lake Zurich, IL 60047.|
|ANDA 074097||Isoflurane USP, 99.9%||Hospira, Inc., 275 North Field Dr., Bldg. H1, Lake Forest, IL 60045.|
|ANDA 076484||Ciprofloxacin Injection USP, 200 mg/20 mL and 400 mg/40 mL||Fresenius Kabi USA, LLC.|
|ANDA 080504||Epinephrine and Lidocaine HCl Injection, 0.01 mg/mL; 2% and 0.02 mg/mL; 2% Lidocaine HCl Injection, 2%.||Belmora LLC, 2231 Crystal Dr., #1000, Arlington, VA 22202.|
|ANDA 083559||Mepivacaine HCl Injection, 3%||Do.|
|ANDA 084315||Dexamethasone Acetate Injectable Suspension USP, EQ 8 mg base/mL||Watson Laboratories, Inc., Subsidiary of Teva Pharmaceuticals USA, Inc., 425 Privet Rd., Horsham, PA 19044.|
|ANDA 084850||Levonordefrin and Mepivacaine HCl Injection, 2%; 0.05 mg/mL||Belmora LLC.|
|ANDA 086389||Lidocaine HCl Viscous Oral Topical Solution USP, 2%||International Medication Systems, Ltd., 1886 Santa Anita Ave., South El Monte, CA 91733.|
|ANDA 087863||Choledyl SA (oxtriphylline) Extended-Release Tablets USP, 400 mg||Warner Chilcott Co., LLC, Subsidiary of Teva Pharmaceuticals USA, Inc., 425 Privet Rd., Horsham, PA 19044.|
Therefore, approval of the applications listed in the table, and all amendments and supplements thereto, is hereby withdrawn as of December 10, 2018. Introduction or delivery for introduction into interstate commerce of products without approved new drug applications violates section 301(a) and (d) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331(a) and (d)). Drug products that are listed in the table that are in inventory on December 10, 2018 may continue to be dispensed until the inventories have been depleted or the drug products have reached their expiration dates or otherwise become violative, whichever occurs first.
End Supplemental Information
Dated: November 6, 2018.
Associate Commissioner for Policy.
[FR Doc. 2018-24605 Filed 11-8-18; 8:45 am]
BILLING CODE 4164-01-P